摘要
目的研究单纯经肝动脉化疗栓塞(TACE)联合肿瘤间质治疗(IT)肝癌的临床疗效及其病理变化。方法将40例肝癌患者分成两组,对照组20例行单纯TACE治疗,实验组20例行TACE联合经皮肝瘤内药物注射碘油化疗药物肿瘤间质治疗。观察两组患者术后1个月瘤灶内碘油沉积情况以及术后6个月肿瘤局控率,2年生存率以及中位生存期。术后1个月肿瘤穿刺活检,观察瘤灶病理改变。结果两组瘤灶碘油沉积率、术后6个月肿瘤局控率、2年生存率以及中位生存期,差异均有统计学意义(P<0.05)。对照组瘤灶病理以大量肿瘤细胞凝固性坏死改变为主,实验组则可见大量肿瘤细胞脂肪样变性坏死。结论TACE联合肿瘤间质治疗肝癌,可以显著提高瘤灶碘油沉积率,提高肿瘤局控率,降低TACE术后残留瘤灶复发率,延长患者生存期,减轻介入术后不良反应。
Objective To explore the clinical significance in transcatheter arterial chemoembolizaton combined with interstitial therapy for liver cancer and the changes in pathology. Methods 40 patients with liver cancer were divided into two groups,control group received transcatheter arterial chemoembolizaton, and trial group received transcatheter arterial chemoembolizaton combined with interstitial therapy of percutaneous lipiodol and anti-cancer agents injection intratumorly for liver cancer. Then observed the percent of lipiodol deposited in the tumor,local control ratio of 6 months, survive rate in 2 years, the median survival time, and puncher biopsy one month postoperative. Results There was significant difference in the percent of lipiodol deposited in the tumor, local control ratio of 6 months,survive rate in 2 years, the median survival time between control and trial groups（P〈0.05）. And there was a great quantity of coagulation necrosis of tumor focus in control group pathology postoperative, but a great quantity of lipoid degeneration necrosis in trial group pathology postoperative. Conclusion Transcatheter arterial chemoembolizaton combined with interstitial therapy of percutaneous lipiodol and anti-cancer agents injection intratumorly for liver cancer may improve the percent of lipiodol deposited in the tumor and local control ratio of 6 months,extend the life span,drop recurrence rate of remained fo cus tumor and relieve adverse effect postoperative.
出处
《重庆医学》
CAS
CSCD
北大核心
2010年第8期924-926,I0002,共4页
Chongqing medicine
关键词
肝癌
TACE
瘤内注射
碘油
liver cancer
transeatheter arterial chemoembolizaton
injection intratumor
lipiodol
interstitial therapy
